Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
32 results:
1. The diagnostic and prognostic potential of the egfr/MUC4/MMP9 axis in glioma patients.
Quesnel A; Coles N; Polvikoski TM; Karagiannis GS; Angione C; Islam M; Khundakar AA; Filippou PS
Sci Rep; 2022 Nov; 12(1):19868. PubMed ID: 36400876
[TBL] [Abstract] [Full Text] [Related]
2. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract] [Full Text] [Related]
4. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis.
Vuong HG; Tran TTK; Ngo HTT; Pham TQ; Nakazawa T; Fung KM; Hassell L; Katoh R; Kondo T
Eur J Neurol; 2019 Mar; 26(3):379-387. PubMed ID: 30298540
[TBL] [Abstract] [Full Text] [Related]
6. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
[TBL] [Abstract] [Full Text] [Related]
7. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of egfr and PTEN: new opportunities for selected targeted therapies.
Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
[TBL] [Abstract] [Full Text] [Related]
8. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.
Meng D; Chen Y; Yun D; Zhao Y; Wang J; Xu T; Li X; Wang Y; Yuan L; Sun R; Song X; Huai C; Hu L; Yang S; Min T; Chen J; Chen H; Lu D
Oncotarget; 2015 Mar; 6(7):4901-19. PubMed ID: 25669971
[TBL] [Abstract] [Full Text] [Related]
9. Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.
Conroy S; Kruyt FA; Joseph JV; Balasubramaniyan V; Bhat KP; Wagemakers M; Enting RH; Walenkamp AM; den Dunnen WF
PLoS One; 2014; 9(12):e115687. PubMed ID: 25546404
[TBL] [Abstract] [Full Text] [Related]
10. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract] [Full Text] [Related]
11. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract] [Full Text] [Related]
12. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
[TBL] [Abstract] [Full Text] [Related]
13. Molecular interactions of erbb1 (egfr) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.
Petrás M; Lajtos T; Friedländer E; Klekner A; Pintye E; Feuerstein BG; Szöllosi J; Vereb G
Neuro Oncol; 2013 Aug; 15(8):1027-40. PubMed ID: 23595626
[TBL] [Abstract] [Full Text] [Related]
14. Molecular characteristics of glioblastoma with 1p/19q co-deletion.
Mizoguchi M; Yoshimoto K; Ma X; Guan Y; Hata N; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
Brain Tumor Pathol; 2012 Jul; 29(3):148-53. PubMed ID: 22736234
[TBL] [Abstract] [Full Text] [Related]
15. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
[TBL] [Abstract] [Full Text] [Related]
16. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
[TBL] [Abstract] [Full Text] [Related]
17. [Morphological classification of glioblastomas].
Figarella-Branger D; Bouvier C; Moroch J; Michalak S; F Burel-Vandenbos
Neurochirurgie; 2010 Dec; 56(6):459-63. PubMed ID: 20864138
[TBL] [Abstract] [Full Text] [Related]
18. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Uhm JH; Ballman KV; Wu W; Giannini C; Krauss JC; Buckner JC; James CD; Scheithauer BW; Behrens RJ; Flynn PJ; Schaefer PL; Dakhill SR; Jaeckle KA
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):347-53. PubMed ID: 20510539
[TBL] [Abstract] [Full Text] [Related]
19. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract] [Full Text] [Related]
20. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract] [Full Text] [Related]
[Next]
